Home » Stocks » ARTH

Arch Therapeutics, Inc. (ARTH)

Stock Price: $0.1086 USD -0.0139 (-11.35%)
Updated May 14, 2021 3:58 PM EDT - Market closed
Market Cap 25.72M
Revenue (ttm) 10,000
Net Income (ttm) -5.25M
Shares Out 236.72M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE 10.75
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $0.1086
Previous Close $0.1225
Change ($) -0.0139
Change (%) -11.35%
Day's Open 0.1200
Day's Range 0.1073 - 0.1292
Day's Volume 428,907
52-Week Range 0.1000 - 0.2300

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Honors for Highest Scoring Poster Abstract in Case Series/Study Category Confirms Commercialization Opportunities for AC5® Advanced Wound System Honors for Highest Scoring Poster Abstract in Case Series...

6 days ago - GlobeNewsWire

Company Prepares for Next Stage of Growth Company Prepares for Next Stage of Growth

1 week ago - GlobeNewsWire

Additional case studies support the broad potential of AC5® Advanced Wound System in chronic and non-healing wounds Additional case studies support the broad potential of AC5® Advanced Wound System in c...

2 weeks ago - GlobeNewsWire

2021: Executing on Opportunities and Preparing for the Future 2021: Executing on Opportunities and Preparing for the Future

3 weeks ago - GlobeNewsWire

Management to provide corporate update on Dermal Sciences and BioSurgery Management to provide corporate update on Dermal Sciences and BioSurgery

2 months ago - GlobeNewsWire

AC5® Advanced Wound System Commercialization Has Commenced AC5® Advanced Wound System Commercialization Has Commenced

2 months ago - GlobeNewsWire

FRAMINGHAM, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announc...

3 months ago - GlobeNewsWire

FRAMINGHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced tod...

4 months ago - GlobeNewsWire

Partnership provides US government facilities access and product distribution support Partnership provides US government facilities access and product distribution support

4 months ago - GlobeNewsWire

FRAMINGHAM, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced tod...

5 months ago - GlobeNewsWire

Financing with long-term shareholders provides flexibility during product roll-out Financing with long-term shareholders provides flexibility during product roll-out

6 months ago - GlobeNewsWire

Clinical case reports and animal studies that were presented support the broad potential of AC5 Advanced Wound System in a range of complicated acute and chronic wounds Clinical case reports and animal ...

6 months ago - GlobeNewsWire

Live moderated video webcast discussion of AC5 Advanced Wound System among management and Key Opinion Leaders on Wednesday, October 28th at 12:00 PM ET Live moderated video webcast discussion of AC5 Adv...

6 months ago - GlobeNewsWire

A series of clinical case reports and animal studies support the broad potential of AC5 Advanced Wound System in a range of complicated acute and chronic wounds A series of clinical case reports and ani...

7 months ago - GlobeNewsWire

Arch Therapeutics has FDA and EMA approval for AC5.

7 months ago - Seeking Alpha

New York, New York--(Newsfile Corp. - September 22, 2020) -  Arch Therapeutics, Inc. (OTCQB: ARTH) has cleared significant hurdles to commercialize its AC5 Advanced Wound System and AC5 Topical Hemostat...

7 months ago - Newsfile Corp

Arch Therapeutics Reports First Pressure Ulcer Case Results

8 months ago - Seeking Alpha

FRAMINGHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...

8 months ago - GlobeNewsWire

FRAMINGHAM, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today ...

8 months ago - GlobeNewsWire

Emerging technology presentation demonstrates use of AC5-GTM in submucosal lifting and management of gastrointestinal bleeding during porcine endoscopic procedures. Emerging technology presentation demo...

9 months ago - GlobeNewsWire

Emerging Technology video presentation describing swine studies using AC5-GTM for submucosal lifting and management of gastrointestinal bleeding in endoscopic resection Emerging Technology video present...

9 months ago - GlobeNewsWire

Live video moderated discussion with Dr. Terrence Norchi, CEO, on Monday, June 15, at 12:00 PM ET, immediately followed by an interactive Q&A session Live video moderated discussion with Dr. Terrence No...

11 months ago - GlobeNewsWire

Financing with long-term shareholders provides flexibility during product roll-out Financing with long-term shareholders provides flexibility during product roll-out

11 months ago - GlobeNewsWire

These sectors came up with stellar earnings beat in the recent cycle. Investors can play the associated stocks that delivered an earnings surprise.

Other stocks mentioned: AAXN, BYND, CENX, CHWY, DXCM, ORN, PCH ...
11 months ago - Zacks Investment Research

Only funds with coverage >100% are considered.

1 year ago - Seeking Alpha

About ARTH

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company ... [Read more...]

Industry
Biotechnology
Founded
2006
Stock Exchange
OTCMKTS
Ticker Symbol
ARTH
Full Company Profile

Financial Performance

Financial Statements